Synthesis, Biological Evaluation and In Silico Investigation of Novel Functionalized Imidazole-Based KDM6 Inhibitors
El-Araby, A., Qassem, O., El-Sawy, E., El-Razaz, E., Abouzid, K., Serya, R. (2021). Synthesis, Biological Evaluation and In Silico Investigation of Novel Functionalized Imidazole-Based KDM6 Inhibitors. EKB Journal Management System, 64(3), 1575-1582. doi: 10.21608/ejchem.2020.38209.2790
Amr Mostafa El-Araby; Omar Magdy Qassem; Ezzat Ashraf El-Sawy; Eman Zaghlol El-Razaz; Khaled Abouzid; Rabah Ahmed Taha Serya. "Synthesis, Biological Evaluation and In Silico Investigation of Novel Functionalized Imidazole-Based KDM6 Inhibitors". EKB Journal Management System, 64, 3, 2021, 1575-1582. doi: 10.21608/ejchem.2020.38209.2790
El-Araby, A., Qassem, O., El-Sawy, E., El-Razaz, E., Abouzid, K., Serya, R. (2021). 'Synthesis, Biological Evaluation and In Silico Investigation of Novel Functionalized Imidazole-Based KDM6 Inhibitors', EKB Journal Management System, 64(3), pp. 1575-1582. doi: 10.21608/ejchem.2020.38209.2790
El-Araby, A., Qassem, O., El-Sawy, E., El-Razaz, E., Abouzid, K., Serya, R. Synthesis, Biological Evaluation and In Silico Investigation of Novel Functionalized Imidazole-Based KDM6 Inhibitors. EKB Journal Management System, 2021; 64(3): 1575-1582. doi: 10.21608/ejchem.2020.38209.2790

Synthesis, Biological Evaluation and In Silico Investigation of Novel Functionalized Imidazole-Based KDM6 Inhibitors

Egyptian Journal of Chemistry
Article 45, Volume 64, Issue 3, March 2021, Page 1575-1582  XML PDF (588.92 K)
Document Type: Original Article
DOI: 10.21608/ejchem.2020.38209.2790
View on SCiNiTO View on SCiNiTO
Authors
Amr Mostafa El-Araby1; Omar Magdy Qassem2; Ezzat Ashraf El-Sawy1; Eman Zaghlol El-Razaz1; Khaled Abouzidorcid 3; Rabah Ahmed Taha Serya email orcid 4
1Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
2Pharmaceutical Chemistry department , Faculty of pharmacy, Ain Shams University, Cairo, Egypt
3Professor of pharmaceutical chemistry Dean of the Faculty of Pharmacy, University of Sadat City Sadat City, Menoufia, Egypt
4Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
Abstract
Epigenetic markers of the cellular genome are major controllers of the transcriptional level of various genes in physiological and pathological states. These markers are written and erased by epigenetic factors which have been recently studied as potential therapeutic targets of various disease states. Histone lysine demethylases are an example of these epigenetic factors. The subfamily number 6 of these enzymes (KDM6) are an understudied group of histone demethylases which have been recently connected to cancers and inflammation. In this work, we conducted a rational and computer-aided approach to design and synthesize KDM6 inhibitors. The designed inhibitors are imidazole-based and are functionalized with variable metal-chelating group to be able to chelate the active site ferrous ion. One of the synthesized compounds, compound 6, was able to inhibit KDM6-expressing cancer cell lines by more than 50%. Molecular docking studies suggest that this compound is able to achieve important active site interactions and coordinate the active site metal through a tridentate interaction. Furthermore a correlation was established between the structural features and CLogP of the tested compounds and their activity. These results represent a promising starting point for the future development of novel KDM6 inhibitors with higher potency.
Keywords
KDM6; JMJD3; GSK-J1; Cervical Cancer; Prostate Cancer; NSCLC; Docking
Statistics
Article View: 558
PDF Download: 278